HR 8000, the END 7-OH Act, amends the Controlled Substances Act to schedule synthetic 7-hydroxymitragynine as a Schedule I controlled substance while explicitly protecting naturally occurring 7-hydroxymitragynine found in kratom leaf. The bill targets only synthetic versions of this alkaloid compound, leaving the natural kratom plant and its traditional forms completely unrestricted. This surgical approach addresses the problem of dangerous mislabeled synthetic products flooding the market without restricting consumer access to the plant itself. The measure aligns with FDA guidance distinguishing between synthetic compounds and natural plant materials, and reflects positions endorsed by the Global Kratom Coalition. By scheduling only the synthetic variant, the bill protects public health from dangerous imitations while preserving patient choice and farmer livelihoods.

Why It Matters to MAHA

This bill embodies the MAHA principle of targeted regulation that protects consumers without eliminating choice. Rather than imposing a blanket ban on kratom, HR 8000 uses precision regulatory policy to eliminate mislabeled and potentially dangerous synthetic products while leaving the natural plant available for adults who choose it. The explicit carve-out for natural kratom demonstrates respect for consumer autonomy and the botanical medicine marketplace that MAHA advocates for. This approach increases market transparency by removing counterfeit synthetic products, allowing consumers to make informed decisions about what they actually purchase. The bill also protects farmers and legitimate kratom vendors from unfair competition by bad actors peddling dangerous synthetic imposters.